Emu Oil and Saireito in combination reduce tumour development and clinical indicators of disease in a mouse model of colitis-associated colorectal cancer.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsChartier, Lauren C
Howarth, Gordon S
MetadataShow full item record
CitationChartier LC, Fujino J, Howarth GS, Freysdottir J, Hardardottir I, Mashtoub S. Emu Oil and Saireito in combination reduce tumour development and clinical indicators of disease in a mouse model of colitis-associated colorectal cancer. Biomed Pharmacother. 2021 Jun;138:111478. doi: 10.1016/j.biopha.2021.111478.
AbstractBackground: Emu Oil (EO) previously demonstrated therapeutic potential in a mouse model of colitis-associated CRC (CA-CRC). Saireito, a traditional Japanese medicine, has not been investigated in CA-CRC. Aim: To determine whether EO and Saireito could be therapeutic in an azoxymethane (AOM)/dextran sulphate sodium (DSS) model of CA-CRC. Methods: Female C57BL/6 mice were assigned to groups (n = 10/group); 1) saline control, 2) saline+Saireito, 3) saline+EO, 4) saline+EO/Saireito, 5) AOM/DSS control, 6) AOM/DSS+Saireito, 7) AOM/DSS+EO and 8) AOM/DSS+EO/Saireito. Mice were intraperitoneally injected with saline or AOM (7.4 mg/kg) on day 0 and underwent three DSS/water cycles (2%w/v DSS for 7 days, 14 days water). Mice were orally-gavaged with either water (80 µL), Saireito (80 µL), EO (80 µL) or EO/Saireito (160 µL; 80 µL EO + 80 µL Saireito) thrice weekly. Daily bodyweight and disease activity index (DAI) were recorded and colonoscopies performed on days 20, 41 and 62. Mice were euthanized on day 63. p < 0.05 was considered statistically significant. Results: AOM/DSS induced significant bodyweight loss throughout the trial (max -36%), which was attenuated by Saireito (max +7%), EO (max +5%) and EO/Saireito (max +14%; p < 0.05). AOM/DSS increased DAI compared to saline controls (p < 0.05), which was reduced by Saireito, EO and EO/Saireito (p < 0.05). All treatments reduced colonoscopically-assessed colitis severity (days 20 and 41; p < 0.05). EO/Saireito further decreased colitis severity compared to Saireito and EO alone (day 20; p < 0.05). Finally, EO and EO/Saireito resulted in fewer colonic tumours compared to AOM/DSS controls (p < 0.05). Conclusion: Combined EO and Saireito reduced disease and tumour development in AOM/DSS mice, suggesting therapeutic potential in CA-CRC. Keywords: Colorectal cancer; Emu Oil; Kampo medicine; Mouse model; Nutraceuticals; Ulcerative colitis.
DescriptionTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Download
RightsCopyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
- Emu oil and grape seed extract reduce tumour burden and disease parameters in murine colitis-associated colorectal cancer.
- Authors: Chartier LC, Howarth GS, Trinder D, Mashtoub S
- Issue date: 2021 Feb 25
- Emu Oil Attenuates Disease Severity and Results in Fewer Large Colonic Tumors in a Mouse Model of Colitis-Associated Colorectal Cancer.
- Authors: Mashtoub S, Chartier LC, Trinder D, Lawrance IC, Howarth GS
- Issue date: 2021 Apr 12
- Chemotherapy-induced mucositis development in a murine model of colitis-associated colorectal cancer.
- Authors: Chartier LC, Howarth GS, Mashtoub S
- Issue date: 2020 Jan
- Emu Oil reduces disease severity in a mouse model of chronic ulcerative colitis.
- Authors: Safaeian R, Howarth GS, Lawrance IC, Trinder D, Mashtoub S
- Issue date: 2019 Mar
- Emu Oil Improves Clinical Indicators of Disease in a Mouse Model of Colitis-Associated Colorectal Cancer.
- Authors: Chartier LC, Howarth GS, Lawrance IC, Trinder D, Barker SJ, Mashtoub S
- Issue date: 2018 Jan